Olema Pharmaceuticals, Inc. OLMA Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $176.31M+11.8% | $157.7M+7.4% | $146.78M+4.8% | $140.05M+11.8% | $125.26M+0.6% | ||
| $25.51M+21.5% | $21M+12.9% | $18.61M+9.0% | $17.08M-2.6% | $17.53M-1.2% | ||
| $201.81M+12.9% | $178.7M+8.1% | $165.38M+5.3% | $157.13M+10.0% | $142.79M+0.4% | ||
| $201.81M+12.9% | $178.7M+8.1% | $165.38M+5.3% | $157.13M+10.0% | $142.79M+0.4% | ||
| -$201.81M-12.9% | -$178.7M-8.1% | -$165.38M-5.3% | -$157.13M-10.0% | -$142.79M-0.4% | ||
| $16.48M+1.6% | $16.22M+4.6% | $15.51M+4.9% | $14.79M+6.7% | $13.85M+9.2% | ||
| $16.66M+2.5% | $16.25M+5.3% | $15.43M+4.0% | $14.83M+6.7% | $13.9M+8.7% | ||
| -$185.15M-14.0% | -$162.45M-8.3% | -$149.96M-5.4% | -$142.3M-10.4% | -$128.89M+0.4% | ||
| -$2.03-8.6% | -$1.87-6.2% | -$1.76+5.9% | -$1.87+1.6% | -$1.90+9.5% | ||
| -$2.03-8.6% | -$1.87-6.2% | -$1.76+5.9% | -$1.87+1.6% | -$1.90+9.5% | ||
| 361M+5.1% | 343.7M+9.0% | 315.4M+9.9% | 286.9M+11.3% | 257.7M+13.1% | ||
| 361M+5.1% | 343.7M+9.0% | 315.4M+9.9% | 286.9M+11.3% | 257.7M+13.1% | ||
| $184K+700% | $23K— | —— | —— | —— | ||
| -$201.81M-12.9% | -$178.7M-8.1% | -$165.38M-5.3% | -$157.13M-10.0% | -$142.79M-0.4% | ||
| -$201.33M-13.0% | -$178.21M-8.0% | -$164.96M-5.3% | -$156.66M-10.0% | -$142.36M-0.3% | ||
| -$201.33M-13.0% | -$178.21M-8.0% | -$164.96M-5.3% | -$156.66M-10.0% | -$142.36M-0.3% | ||
| -$201.81M-12.9% | -$178.7M-8.1% | -$165.38M-5.3% | -$157.13M-10.0% | -$142.79M-0.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Olema Pharmaceuticals, Inc. profitable?
- Olema Pharmaceuticals, Inc. is not currently profitable: it reported a net loss of $185.2M over the trailing twelve months.
- What is Olema Pharmaceuticals, Inc.'s earnings per share?
- Olema Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $-2.03.
- Where does Olema Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from Olema Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.